infliximab vs infliximab-dyyb (Zymfentra)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
infliximab · Remicade
Marketed by Johnson & Johnson
NCT00094458 · Phase 3 · completed
This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).
Next expected readout: November 2026 · NCT05906576 (registry estimate)
Reported efficacy
Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) (met)
Result source: NCT00094458
infliximab-dyyb (Zymfentra)
Marketed by Celltrion
NCT03945019 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.
Next expected readout: December 2026 · NCT06064864 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | infliximab | infliximab-dyyb (Zymfentra) |
|---|---|---|
| Clinical remission (induction) | 47.3% vs 34.1%vs Azathioprine + PlaceboNCT000944585 other results
| —Not reported |
| Endoscopic response (induction) | —Not posted · NCT00004941 | —Not reported |
| Clinical remission (maintenance) | 66% vs 54.7%vs Azathioprine + PlaceboNCT000944587 other results
| —Not reported |
| Endoscopic response (maintenance) | —Not posted · NCT00004941 | —Not reported |
Clinical remission (induction)
- infliximab
- 47.3% vs 34.1%vs Azathioprine + PlaceboNCT00094458
5 other results
- 59.8% vs 34.1% NCT00094458
- 49.1% vs 27.6% NCT00094458
- 52.1% vs 27.6% NCT00094458
- 32.5% vs 17.6% NCT00094458
- 36.7% vs 17.6% NCT00094458
- infliximab-dyyb (Zymfentra)
- —Not reported
Endoscopic response (induction)
- infliximab
- —Not posted · NCT00004941
- infliximab-dyyb (Zymfentra)
- —Not reported
Clinical remission (maintenance)
- infliximab
- 66% vs 54.7%vs Azathioprine + PlaceboNCT00094458
7 other results
- 74.1% vs 54.7% NCT00094458
- 72.2% vs 58.7% NCT00094458
- 73.1% vs 58.7% NCT00094458
- 66% vs 61.3% NCT00094458
- 69.4% vs 61.3% NCT00094458
- 47.9% vs 31.8% NCT00094458
- 60.4% vs 31.8% NCT00094458
- infliximab-dyyb (Zymfentra)
- —Not reported
Endoscopic response (maintenance)
- infliximab
- —Not posted · NCT00004941
- infliximab-dyyb (Zymfentra)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
infliximab-dyyb (Zymfentra): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. infliximab: 4 of 4 rows · infliximab-dyyb (Zymfentra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | infliximab |
|---|---|
| Dropout rate | 28.4%Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results34.3%Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 0% NCT01580670 · Phase 3 · monotherapy 13.3% NCT00805766 · Phase 3 · monotherapy 18.2% NCT00688636 · Phase 4 · registry result, not featured evidence 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 16.6%Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results11.8%Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 — NCT01580670 · Phase 3 · monotherapy 2.2% NCT00805766 · Phase 3 · monotherapy 18.2% NCT00688636 · Phase 4 · registry result, not featured evidence 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Serious AEs | —Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results—Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 14%W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 16%W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 1.9%W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 15.5%W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 14.3% NCT01580670 · Phase 3 · monotherapy — NCT00805766 · Phase 3 · monotherapy 9.1% NCT00688636 · Phase 4 · registry result, not featured evidence 0% NCT00791557 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 21.8% abdominal pain 13.4% fatigue 13.4% NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 6 more resultsabdominal pain 9.3% nasopharyngitis 8.3% crohn's disease 5.6% NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 double stranded dna antibody positive 50% gastroenteritis 21.4% headache 21.4% NCT01580670 · Phase 3 · monotherapy infusion reaction 18.2% (placebo 7.7%) abcess 9.1% (placebo 7.7%) bronchitis 9.1% (placebo 0%) NCT00688636 · Phase 4 · registry result, not featured evidence bone marrow suppression 50% infection 50% infusion reaction 50% NCT00791557 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
infliximab
show 3 more results
show 1 more result
show 15 more results
show 15 more results
show 9 more results
show 9 more results
show 13 more results
show 13 more results
show 13 more results
+ 6 further endpoints in the CSV export.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
infliximab · Remicade
Marketed by Johnson & Johnson
NCT01585155 · Phase 3 · completed
No randomization, no blinding (masking: NONE), no control arm, single-group design with only 21 patients — this defaults to 'weak' per the design rules regardless of the favorable-looking remission percentages.
Next expected readout: December 2026 · NCT06839820 (registry estimate)
Reported efficacy
Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
Result source: NCT01585155
infliximab-dyyb (Zymfentra)
Marketed by Celltrion
NCT04205643 · Phase 3 · completed
The trial was randomized, quadruple-blind, and placebo-controlled, with 548 participants enrolled and 438 participants included in the reported maintenance analysis. The hard clinical primary endpoint—clinical remission by the modified Mayo score at week 54—was met, with 127 of 294 participants receiving CT-P13 versus 30 of 144 receiving placebo (p<0.0001).
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | infliximab | infliximab-dyyb (Zymfentra) |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT06614387 | —Not reported |
| Clinical remission (maintenance) | —Trial running · NCT06614387 | —Not reported |
| Clinical response (induction) | —Trial running · NCT06614387 | —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT06614387 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT06614387 | —Not reported |
Clinical remission (induction)
- infliximab
- —Trial running · NCT06614387
- infliximab-dyyb (Zymfentra)
- —Not reported
Clinical remission (maintenance)
- infliximab
- —Trial running · NCT06614387
- infliximab-dyyb (Zymfentra)
- —Not reported
Clinical response (induction)
- infliximab
- —Trial running · NCT06614387
- infliximab-dyyb (Zymfentra)
- —Not reported
Endoscopic improvement (induction)
- infliximab
- —Trial running · NCT06614387
- infliximab-dyyb (Zymfentra)
- —Not reported
Corticosteroid-free remission (maintenance)
- infliximab
- —Trial running · NCT06614387
- infliximab-dyyb (Zymfentra)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
infliximab-dyyb (Zymfentra): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. infliximab: 4 of 4 rows · infliximab-dyyb (Zymfentra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | infliximab |
|---|---|
| Dropout rate | 23.8%a NCT01585155 · Phase 3 · monotherapy show 3 more results47.8%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.2%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 4.8%a NCT01585155 · Phase 3 · monotherapy show 3 more results26.1%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.6%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Serious AEs | 14.3%a NCT01585155 · Phase 3 · monotherapy show 3 more results21.7%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.2%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0% NCT00791557 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a double stranded dna antibody positive 57.1% nasopharyngitis 33.3% acne 9.5% NCT01585155 · Phase 3 · monotherapy show 3 more results5 mg/kg every 12 weeks colitis ulcerative 65.2% upper respiratory tract infection 26.1% pain 17.4% NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5 mg/kg every 8 weeks colitis ulcerative 31.8% upper respiratory tract infection 31.8% fever 27.3% NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 bone marrow suppression 50% infection 50% infusion reaction 50% NCT00791557 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
infliximab
+ 31 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: infliximab's landscape · infliximab-dyyb (Zymfentra)'s landscape